Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Am J Transplant. 2018 Nov;18(11):2818-2822. doi: 10.1111/ajt.14998. Epub 2018 Aug 13.
Primary focal segmental glomerulosclerosis (FSGS) recurs in up to 55% of patients after kidney transplantation. Herein we report the successful management of recurrent FSGS. A 5-year-old boy with primary FSGS received a deceased donor renal transplant. Immediate and fulminant recurrence of FSGS caused anuric graft failure that was resistant to plasmapheresis and rituximab. After exclusion of structural or immunologic damage to the kidney by repeated biopsies, the allograft was retrieved from the first recipient on day 27 and transplanted into a 52-year-old second recipient who had vascular nephropathy. Immediately after retransplantation, the allograft regained function with excellent graft function persistent now at 3 years after transplant. After 2 years on hemodialysis, the boy was listed for kidney retransplantation. To prevent FSGS recurrence, pretreatment with ofatumumab was performed. Nephrotic range proteinuria still occurred after the second transplantation, which responded, however, to daily plasma exchange in combination with ofatumumab. At 8 months after kidney retransplantation graft function is good. The clinical course supports the hypothesis of a circulating permeability factor in the pathogenesis of FSGS. Successful ofatumumab pretreatment implicates a key role of B cells. Herein we provide a description of successful management of kidney failure by FSGS, carefully avoiding waste of organs.
原发性局灶节段性肾小球硬化症(FSGS)在肾移植后高达 55%的患者中复发。在此,我们报告了复发性 FSGS 的成功治疗。一名 5 岁男孩患有原发性 FSGS,接受了已故供体的肾移植。FSGS 的即刻和暴发性复发导致无尿性移植物衰竭,对血浆置换和利妥昔单抗均无反应。在通过重复活检排除对肾脏的结构或免疫损伤后,于第 27 天从第一受者取回移植物并移植到患有血管性肾病的 52 岁第二受者。在重新移植后,移植物立即恢复功能,现在移植后 3 年仍保持良好的移植物功能。在接受了 2 年的血液透析后,该男孩被列入了肾脏再次移植的名单。为了预防 FSGS 复发,在第二次移植前进行了奥法妥珠单抗预处理。然而,第二次移植后仍出现肾病范围的蛋白尿,尽管如此,每日血浆置换联合奥法妥珠单抗治疗后仍有效。在肾再次移植后 8 个月,移植物功能良好。临床过程支持 FSGS 发病机制中存在循环通透性因子的假说。奥法妥珠单抗预处理的成功暗示了 B 细胞的关键作用。在此,我们提供了一个成功管理 FSGS 导致的肾衰竭的描述,仔细避免了器官的浪费。